Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
NUTX · Nasdaq · United States · Services-Business Services, Nec
In shortNutex Health Inc. is profitable, generates cash and holds more cash than debt, with revenue growing (+82.4% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 31.5% | 100/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 8.1% | 52/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 30.7% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 54.6% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.41× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.13× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 12.40× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 4.42 | 85/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 28.1% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 3.47× | 100/100 |
| Years with positive free cash flow (last 5) | 4 of 5 | 75/100 |
Weight in the score: 20%
| Profitable years (last 5) | 3 of 5 | 60/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 52.7% | 0/100 |
| Operating margin volatility | 96.6% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 58.6% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 332 | 219 | 248 | 480 | 875 |
| Cost of revenue | 15 | – | – | – | – |
| Gross profit | 179 | 15 | 35 | 196 | 444 |
| Research & development | 0.3 | – | – | – | – |
| Operating income | 170 | (407) | (32) | 131 | 276 |
| Interest expense | 6.2 | 12 | 16 | 20 | 22 |
| Pre-tax income | 169 | (420) | (48) | 110 | 245 |
| Income tax | 1 | 13 | (5.1) | 15 | 64 |
| Net income | 133 | (425) | (46) | 52 | 71 |
| Diluted EPS | $0.22 | −$100.36 | −$10.39 | $9.69 | $10.48 |
| Diluted shares (millions) | – | 4.2 | 4.4 | 5.5 | 6.8 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
4.42 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 6, 2026